4 completed, 1 active not recruiting, 1 no longer available, 1 terminated. 5 Phase 2, 4 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Completed 3, Active not recruiting 1, Terminated 1 |
| Phase 1 | 4 | Completed 3, Terminated 1 |
Follow derazantinib: new trials by email Literature Review of derazantinib trials Research Report on derazantinib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Treatment of Atezolizumab and Derazantinib in Patients With Advanced iCCA With FGFR2 Fusions/Rearrangements Atezolizumab, Derazantinib - Intrahepatic Cholangiocarcinoma | Phase 2 | Active not recruiting | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | 27 | 2022-04-20 | 2025-12-05 |
| Derazantinib Alone or in Combination With Paclitaxel, Ramucirumab or Atezolizumab in Gastric Adenocarcinoma Derazantinib, Derazantinib-paclitaxel-ramucirumab combination - Gastric Adenocarcinoma | Phase 1 / Phase 2 | Terminated | Basilea Pharmaceutica | 47 | 2020-10-06 | 2024-04-04 |
| Mass Balance and Pharmacokinetics Study of Derazantinib in Healthy Male Subjects Derazantinib capsule, [14C]-Derazantinib solution for infusion, [14C]-Derazantinib capsule - Healthy Volunteers | Phase 1 | Completed | Basilea Pharmaceutica | 12 | 2019-08-08 | 2021-01-19 |
| Derazantinib and Atezolizumab in Patients With Urothelial Cancer Derazantinib 300 mg once daily monotherapy, Derazantinib 200 mg once daily + atezolizumab 1200 mg, Derazantinib 300 mg once daily+ atezolizumab 1200 mg - Urothelial Carcinoma | Phase 1 / Phase 2 | Completed | Basilea Pharmaceutica | 95 | 2019-08-02 | 2023-10-13 |
| Derazantinib in Subjects With FGFR2 Gene Fusion-, Mutation- or Amplification- Positive Inoperable or Advanced Intrahepatic Cholangiocarcinoma derazantinib - Intrahepatic Cholangiocarcinoma, Combined Hepatocellular and Cholangiocarcinoma | Phase 2 | Completed | Basilea Pharmaceutica | 148 | 2017-09-28 | 2023-12-19 |
| Phase 1/2 Study of Derazantinib (ARQ 087) in Adult Subjects With Advanced Solid Tumors With FGFR Genetic Alterations Derazantinib low dose range, Derazantinib middle dose range, Derazantinib high dose range - Solid Tumor | Phase 1 / Phase 2 | Completed | Basilea Pharmaceutica | 119 | 2012-12-10 | 2023-06-05 |
| Expanded Access Use of Derazantinib for Advanced Intrahepatic Cholangiocarcinoma (iCCA) With FGFR Genomic Alterations derazantinib - Intrahepatic Cholangiocarcinoma | No longer available | Basilea Pharmaceutica | 2025-04-06 |
Cholangiocarcinoma (4) · Biliary Tract Neoplasms (3) · Liver Neoplasms (3) · Acrocephalosyndactylia (2) · Bile Duct Neoplasms (2) · Carcinoma, Transitional Cell (1) · Neoplasms (1) · Stomach Neoplasms (1) · Urinary Bladder Neoplasms (1)
Basilea Pharmaceutica (6) · Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest (1)
Germany (4) · Italy (4) · United Kingdom (4) · United States (4) · France (3) · South Korea (3) · Spain (3) · Australia (2) · Belgium (2) · Canada (2) · Poland (2) · Switzerland (2) · Argentina (1) · Austria (1) · Brazil (1)
Marc Engelhardt, MD (1) · Nand Singh, MD (1)
PMID 30420614, PMID 27627808, PMID 28972963, PMID 38627238
2019 (1)